{"id":2409,"date":"2017-11-14T18:13:18","date_gmt":"2017-11-14T12:43:18","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=2409"},"modified":"2021-07-24T12:56:52","modified_gmt":"2021-07-24T07:26:52","slug":"the-business-cocktail-35","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-35","title":{"rendered":"Novartis ventures; Bill Gates invests; Arcus Biosciences gains; Denali and Odonate seek funding; Fosun Pharma acquires"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69f38ff367284\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69f38ff367284\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-35\/#Novartis_ventures_itself_into_developing_new_editing_technology\" >Novartis ventures itself into developing new editing technology<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-35\/#Bill_Gates_invests_50_million_in_Dementia_Discovery_Fund\" >Bill Gates invests $50 million in Dementia Discovery Fund<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-35\/#In_the_latest_round_of_funding_Arcus_Biosciences_gains_help_from_Google_Ventures\" >In the latest round of funding, Arcus Biosciences gains help from Google Ventures<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-35\/#Denali_and_Odonate_Therapeutics_seek_funding_by_filing_for_IPOs\" >Denali and Odonate Therapeutics seek\u00a0funding by filing for IPOs<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-35\/#Fosun_Pharma_acquires_Gland_Pharma_as_Khaitan_and_Troutman_Sanders_provide_counsel\" >Fosun Pharma acquires Gland Pharma as Khaitan and Troutman Sanders provide counsel<\/a><\/li><\/ul><\/nav><\/div>\n<h2 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Novartis_ventures_itself_into_developing_new_editing_technology\"><\/span>Novartis ventures itself into developing new editing technology<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p style=\"text-align: justify;\">Novartis has moved beyond CRISPR and CAR-T gene editing technology with its latest deal with Homology Medicines, aiming to improve upon its R&amp;D work in the arena of cell and gene therapy. The deal involves Novartis using the gene editing technology of Homology for developing new treatments related to ophthalmic and hemoglobinopathy diseases. The financial details of the deal has not been revealed but there is an update that Homology will receive an upfront payment as well as an equity investment from Novartis. This has been done to advance the program and explore opportunities for this technology platform. The former also holds rights in the US related to commercialization and can share in the profits with Novartis related to the in vivo application of the technology in hemoglobinopathy program.<\/p>\n<h2 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Bill_Gates_invests_50_million_in_Dementia_Discovery_Fund\"><\/span>Bill Gates invests $50 million in Dementia Discovery Fund<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p style=\"text-align: justify;\">Bill Gates is a billionaire, but also a philanthropic as he recently pledged to invest $50 million to a UK based discovery fund for the development of treatment for Alzheimer\u2019s disease. The fund has been provided to the two year old DDF which is being run by SV Health, a venture capital firm and backed by Biopharma and medical charity organizations. The Alzheimer\u2019s research is focused on discovering and developing drugs that might be able to modify this disease, as this arena has seen little success in past developmental efforts with a handful of drugs having limited efficacy. This time, one of the richest man in the world has provided his financial backing to provide another chance for development of dementia fighting drugs, as this fund will be used to recruit a CEO and direct efforts into driving scientific advisory board into this research arena.<\/p>\n<h2 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"In_the_latest_round_of_funding_Arcus_Biosciences_gains_help_from_Google_Ventures\"><\/span>In the latest round of funding, Arcus Biosciences gains help from Google Ventures<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p style=\"text-align: justify;\">The Immuno-oncology startup, Arcus Bioscience, has generated a great amount of funding from Google\u2019s venture arm to develop clinical programs for dual adenosine receptor agonist and PD-1 antibody for creating combinations that can help treat various cancer subtypes. The company gained around $107 million will help start the Phase I stage of clinical development of AB928 (first-in-class dual adenosine receptor antagonist) and has plans to evaluate AB122 (PD-1 antibody) in combination with the former to create better targeted therapies. Apart from these two, two more candidates, AB680 (CD74 inhibitor) and AB154 (TIGIT antibody) might also receive push towards clinical development.<\/p>\n<h2 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Denali_and_Odonate_Therapeutics_seek_funding_by_filing_for_IPOs\"><\/span>Denali and Odonate Therapeutics seek\u00a0funding by filing for IPOs<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p style=\"text-align: justify;\">Denali Therapeutics is currently developing treatment strategies around 4 pathways of neurodegeneration and has filed to raise $100 million from Nasdaq under the symbol $DNLI. The company is currently working on 5-6 seed programs and its most advanced programs include one for Parkinson\u2019s disease along with another that has a drug in Phase I development. On the other hand, Odonate Therapeutics is also seeking funds to develop oral chemotherapy drugs. This silent biotech is based in San Diego and was founded in 2013. The company plans to file in Nasdaq under $ODT.<\/p>\n<h2 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Fosun_Pharma_acquires_Gland_Pharma_as_Khaitan_and_Troutman_Sanders_provide_counsel\"><\/span>Fosun Pharma acquires Gland Pharma as Khaitan and Troutman Sanders provide counsel<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p style=\"text-align: justify;\">Under the domestic legal counsel of Khaitan &amp; Co. and international legal counsel of Troutman Sanders, Fosun Pharma, on 3 October, acquired US-based Gland Pharma. This acquisition comes as the largest acquisition of an Indian company by a Chinese buyer. The Chinese Pharma company agreed in July 2016 to acquire an 86.08% stake in Gland Pharma for US$1.2 billion, but faced with a failure by the Indian government to consider and clear the deal, it had to settle for a 74% stake valued at US$1.1 billion.<\/p>\n<p style=\"text-align: justify;\"><strong>\u00a0<\/strong><\/p>\n<p style=\"text-align: justify;\">\n","protected":false},"excerpt":{"rendered":"<p>Novartis ventures itself into developing new editing technology Novartis has moved beyond CRISPR and CAR-T gene editing technology with its latest deal with Homology Medicines, aiming to improve upon its R&amp;D work in the arena of cell and gene therapy. The deal involves Novartis using the gene editing technology of Homology for developing new treatments [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[17598,1157,134,1155,204,1158,1160,1165,1045,1159,1162,1163,423,1161,1156,1164],"industry":[17225],"therapeutic_areas":[17235,17229,17228],"class_list":["post-2409","post","type-post","status-publish","format-standard","hentry","category-notizia","tag-arcus-biosciences","tag-bill-gates","tag-business-consultant","tag-consultancy","tag-delveinsight","tag-dementia","tag-denali","tag-fosun-pharma","tag-gland-pharma","tag-google-ventures","tag-ipos","tag-khaitan","tag-novartis","tag-odonate-therapeutics","tag-pharma-consultant","tag-troutman-sanders","industry-pharmaceutical","therapeutic_areas-cell-and-gene-therapy","therapeutic_areas-central-nervous-system","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Novartis ventures; Bill Gates invests; Arcus Biosciences gains<\/title>\n<meta name=\"description\" content=\"Novartis has moved beyond CRISPR and CAR-T gene editing technology with its latest deal with Homology Medicines, aiming to improve upon its R&amp;D...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-35\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novartis ventures; Bill Gates invests; Arcus Biosciences gains\" \/>\n<meta property=\"og:description\" content=\"Novartis has moved beyond CRISPR and CAR-T gene editing technology with its latest deal with Homology Medicines, aiming to improve upon its R&amp;D...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-35\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2017-11-14T12:43:18+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:26:52+00:00\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novartis ventures; Bill Gates invests; Arcus Biosciences gains","description":"Novartis has moved beyond CRISPR and CAR-T gene editing technology with its latest deal with Homology Medicines, aiming to improve upon its R&D...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-35","og_locale":"en_US","og_type":"article","og_title":"Novartis ventures; Bill Gates invests; Arcus Biosciences gains","og_description":"Novartis has moved beyond CRISPR and CAR-T gene editing technology with its latest deal with Homology Medicines, aiming to improve upon its R&D...","og_url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-35","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2017-11-14T12:43:18+00:00","article_modified_time":"2021-07-24T07:26:52+00:00","author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-35","url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-35","name":"Novartis ventures; Bill Gates invests; Arcus Biosciences gains","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"datePublished":"2017-11-14T12:43:18+00:00","dateModified":"2021-07-24T07:26:52+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Novartis has moved beyond CRISPR and CAR-T gene editing technology with its latest deal with Homology Medicines, aiming to improve upon its R&D...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-35"]}]},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":null,"coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Arcus Biosciences<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Bill Gates<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Business Consultant<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">consultancy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Dementia<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Denali<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Fosun Pharma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Gland Pharma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Google Ventures<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">IPOs<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Khaitan<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Novartis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Odonate Therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma consultant<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Troutman Sanders<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Arcus Biosciences<\/span>","<span class=\"advgb-post-tax-term\">Bill Gates<\/span>","<span class=\"advgb-post-tax-term\">Business Consultant<\/span>","<span class=\"advgb-post-tax-term\">consultancy<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">Dementia<\/span>","<span class=\"advgb-post-tax-term\">Denali<\/span>","<span class=\"advgb-post-tax-term\">Fosun Pharma<\/span>","<span class=\"advgb-post-tax-term\">Gland Pharma<\/span>","<span class=\"advgb-post-tax-term\">Google Ventures<\/span>","<span class=\"advgb-post-tax-term\">IPOs<\/span>","<span class=\"advgb-post-tax-term\">Khaitan<\/span>","<span class=\"advgb-post-tax-term\">Novartis<\/span>","<span class=\"advgb-post-tax-term\">Odonate Therapeutics<\/span>","<span class=\"advgb-post-tax-term\">pharma consultant<\/span>","<span class=\"advgb-post-tax-term\">Troutman Sanders<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 8 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Nov 14, 2017","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Nov 14, 2017 6:13 pm","modified":"Updated on Jul 24, 2021 12:56 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2409","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=2409"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2409\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=2409"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=2409"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=2409"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=2409"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=2409"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}